Literature DB >> 28888333

Maternal long chain polyunsaturated fatty acid status and pregnancy complications.

Nisha Wadhwani1, Vidya Patil1, Sadhana Joshi2.   

Abstract

Maternal nutrition plays a crucial role in influencing fetal growth and birth outcome. Any nutritional insult starting several weeks before pregnancy and during critical periods of gestation is known to influence fetal development and increase the risk for diseases during later life. Literature suggests that chronic adult diseases may have their origin during early life - a concept referred to as Developmental Origins of Health and Disease (DOHaD) which states that adverse exposures early in life "program" risks for later chronic disorders. Long chain polyunsaturated fatty acids (LCPUFA), mainly omega-6 and omega-3 fatty acids are known to have an effect on fetal programming. The placental supply of optimal levels of LCPUFA to the fetus during early life is extremely important for the normal growth and development of both placenta and fetus. Any alteration in placental development will result in adverse pregnancy outcome such as gestational diabetes mellitus (GDM), preeclampsia, and intrauterine growth restriction (IUGR). A disturbed materno-fetal LCPUFA supply is known to be linked with each of these pathologies. Further, a disturbed LCPUFA metabolism is reported to be associated with a number of metabolic disorders. It is likely that LCPUFA supplementation during early pregnancy may be beneficial in improving the health of the mother, improving birth outcome and thereby reducing the risk of diseases in later life.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DOHaD; Gestational diabetes mellitus; Intrauterine growth restriction; LCPUFA; Preeclampsia; Pregnancy; Pregnancy outcome

Mesh:

Substances:

Year:  2017        PMID: 28888333     DOI: 10.1016/j.plefa.2017.08.002

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  6 in total

Review 1.  Micronutrient supplementation in pregnancy: Who, what and how much?

Authors:  F Parisi; I di Bartolo; V M Savasi; I Cetin
Journal:  Obstet Med       Date:  2018-05-04

Review 2.  The effects of omega-3 fatty acids supplementation on metabolic status in pregnant women: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Elaheh Amirani; Zatollah Asemi; Omid Asbaghi; Alireza Milajerdi; Željko Reiner; Mohammad Ali Mansournia; Jamal Hallajzadeh; Bahram Moazzami; Shahla Chaichian
Journal:  J Diabetes Metab Disord       Date:  2020-06-06

3.  Investigating N-3 Fatty Acids to prevent Neonatal Tobacco-related outcomeS (INFANTS): study protocol for a double-blind, randomized, placebo-controlled parallel clinical trial of n-3 polyunsaturated fatty acids in pregnant smokers.

Authors:  Harvey J Murff; Robert A Greevy; Reesha S Sanghani; Katherine E Hartmann; Tina V Hartert; Cornelia R Graves; Scott S Lee; Hilary A Tindle
Journal:  Trials       Date:  2021-12-14       Impact factor: 2.279

4.  Effect of Maternal Docosahexaenoic Acid (DHA) Supplementation on Offspring Neurodevelopment at 12 Months in India: A Randomized Controlled Trial.

Authors:  Shweta Khandelwal; Dimple Kondal; Monica Chaudhry; Kamal Patil; Mallaiah Kenchaveeraiah Swamy; Deepa Metgud; Sandesh Jogalekar; Mahesh Kamate; Gauri Divan; Ruby Gupta; Dorairaj Prabhakaran; Nikhil Tandon; Usha Ramakrishnan; Aryeh D Stein
Journal:  Nutrients       Date:  2020-10-03       Impact factor: 5.717

Review 5.  Polyunsaturated Fatty Acids and Their Metabolites in Hyperemesis Gravidarum.

Authors:  Richard Lindberg; Maria Lindqvist; Miles Trupp; Marie-Therese Vinnars; Malin L Nording
Journal:  Nutrients       Date:  2020-11-04       Impact factor: 5.717

6.  Association of circulating omega 3, 6 and 9 fatty acids with gestational diabetes mellitus: a systematic review.

Authors:  Shaghayegh Hosseinkhani; Hojat Dehghanbanadaki; Hossein Aazami; Parvin Pasalar; Mojgan Asadi; Farideh Razi
Journal:  BMC Endocr Disord       Date:  2021-06-15       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.